Regulatory approval was supported by a statistically significant improvement in 1‑year moderate‑to‑severe cGVHD‑free survival ...

Daniel Ermann, MD, discusses how clinical and real-world data drive his discussions with older CLL patients regarding ...

Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL ...

She specifically discusses the available treatment options in frontline EGFR mutation–positive advanced non–small cell lung cancer and what particular clinical and lifestyle benefits are provided by ...

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims ...

Explore how oncologists battle information overload, navigate conflicting trial data, and weigh AI tools while keeping ...

Misako Nagasaka, MD, PhD, discusses practical considerations for oncologists implementing subcutaneous (SC) vs intravenous (IV) amivantamab plus lazertinib in the frontline setting for patients with ...

Dr. Monty Pal discusses the historical role of the International Metastatic Renal Cell Database Consortium (IMDC) risk ...

Explore how genomics, comorbidities, and patient goals steer frontline CLL therapy, from fixed-duration venetoclax regimens to continuous BTK inhibitors. In an interview with Targeted Oncology at the ...

Dr. Monty Pal introduces the program by outlining the evolving treatment landscape for advanced renal cell carcinoma (RCC) ...

Misako Nagasaka, MD, PhD, describes the tolerability results with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced non–small cell lung cancer from ...

Misako Nagasaka, MD, PhD, discusses the overall response rate and duration of response with subcutaneous (SC) amivantamab plus lazertinib in patients with treatment-naïve, EGFR-mutated advanced ...